Xenobiotic Therapy – Definition and Application

What Is Xenobiotic Therapy?

The term xenobiotic therapy is derived from the Greek words xenos (foreign) and bios (life). It describes the therapeutic use of xenobiotics – substances that are foreign to the human body and do not occur naturally in human metabolism. In clinical practice, this encompasses a wide range of substances, including pharmaceutical drugs, chemotherapeutic agents, antibiotics, industrially produced compounds, and certain plant-derived substances used at pharmacological concentrations.

Substance Classes in Xenobiotic Therapy

Xenobiotic therapy includes a diverse range of substance categories:

• Synthetic pharmaceuticals: Chemically manufactured active substances such as analgesics, antibiotics, or cytostatics.
• Semi-synthetic substances: Compounds derived from natural precursors but chemically modified (e.g., semi-synthetic penicillins).
• Industrial chemicals with therapeutic potential: Compounds not originally developed for medical use but applied therapeutically.
• High-concentration plant-derived xenobiotics: Extracts used in doses exceeding their natural occurrence in food or environment.

Mechanism of Action

Xenobiotics exert their effects by specifically interfering with biological processes in the human body. Common mechanisms include:

• Enzyme inhibition or activation: Xenobiotics can modulate enzyme activity involved in disease processes.
• Receptor binding: Many active substances bind to specific cell receptors, thereby blocking or activating certain signaling pathways.
• DNA interaction: Cytostatic agents, in particular, interfere with DNA replication in cancer cells.
• Inhibition of pathogens: Antibiotics and antivirals suppress the growth of bacteria or viruses.

Metabolism of Xenobiotics

The human body is equipped with specialized enzyme systems to process and eliminate xenobiotics. The most important of these is the cytochrome P450 (CYP) system located in the liver. This system catalyzes the biotransformation of foreign substances into water-soluble metabolites, which can then be excreted via the kidneys or bile. This process – known as the hepatic first-pass effect – significantly influences the bioavailability of many xenobiotic substances.

Areas of Application

Xenobiotic therapy is applied across numerous medical specialties:

• Oncology: Use of cytostatics and targeted therapies for cancer treatment.
• Infectious disease: Antibiotics, antivirals, and antifungals for combating infections.
• Cardiology: Cardioactive substances such as beta-blockers, ACE inhibitors, or anticoagulants.
• Psychiatry and neurology: Psychotropic drugs, antiepileptics, and neuroprotective agents.
• Rheumatology and immunology: Immunosuppressants and biologics.

Risks and Side Effects

Because xenobiotics are foreign to the body, they can trigger adverse reactions. The most common risks include:

• Hepatotoxicity: Liver damage resulting from intensive hepatic metabolism.
• Nephrotoxicity: Kidney damage occurring during renal excretion.
• Allergic reactions: Immune responses triggered by the foreign substance.
• Drug interactions: Interference with other medications through competition for metabolic enzymes (e.g., CYP inhibition or induction).
• Mutagenicity and carcinogenicity: Certain xenobiotics may damage genetic material or promote cancer development upon long-term exposure.

Regulation and Safety

Medicinal products used as xenobiotics are subject to strict approval procedures in the EU, overseen by the European Medicines Agency (EMA). Clinical trials in phases I through III, along with ongoing pharmacovigilance after market authorization, ensure a high level of patient safety.

References

1. Klaassen, C. D. (ed.) – Casarett and Doull's Toxicology: The Basic Science of Poisons. McGraw-Hill Education, 9th edition (2019).
2. Hodgson, E. – A Textbook of Modern Toxicology. Wiley-Interscience, 4th edition (2010).
3. European Medicines Agency (EMA) – Guidelines on the evaluation of medicinal products. Available at: https://www.ema.europa.eu (accessed 2024).